Sign Out
Specific drug-drug interaction studies have not been conducted with zoledronic acid. Zoledronic acid is not systemically metabolised and does not affect human cytochrome P450 enzymes in vitro (see PHARMACOLOGY: Pharmacokinetics under Actions). Zoledronic acid is not highly bound to plasma proteins (approximately 23 to 40% bound) and interactions resulting from displacement of highly protein-bound drugs are therefore unlikely. Zoledronic acid is eliminated by renal excretion.
Drugs that could Impact Renal Function: Caution is indicated when Aclasta is administered in conjunction with medicinal products that can significantly impact renal function (e.g. aminoglycosides or diuretics that may cause dehydration).
Drugs Primarily Excreted by the Kidney: In patients with renal impairment, the systemic exposure to concomitant medicinal products that are primarily excreted via the kidneys may increase.
Continue with Google